I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Vericel (VCEL) investor converts Series A Preferred Stock

November 29, 2016

  Electing to convert 1,250 shares of preferred stock into 1.25 M shares with shares falling -$0.03 - SELL  

Juno Therapeutics (JUNO) JCAR015 P2 ROCKET trial on HOLD,

November 23, 2016

  SELL, pre-market pricing is DOWN -$0.38 or -1.27%  

Fate Therapeutics (FATE), a $13.30 preferred combined with a $2.66 per share private placement for proceeds of $57 M

November 22, 2016

  The private placement is being led by Redmile Group LLC with participation from BVF Partners L.P., EcoR1 Capital LLC and Franklin Advisers, Inc. as well as certain individual investors including members of the FATE’s Board of Directors. ​FATE does it again ...  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.